Telo Genomics Corp.TELO.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · telodx.com

Telo Genomics Corp. is a Canadian molecular diagnostics company headquartered in Toronto, Ontario, developing the TeloView platform for telomere-based disease prediction. The platform measures the 3D structure and spatial organization of telomeres to predict disease risks and treatment outcomes in oncology and neurological diseases. The company's lead product, TeloView-SMM, targets patients with smoldering multiple myeloma at high risk of progression to active disease.

Key ratios

ROA

-119.8%TTM

2025 -179.6%2024 -87.3%2023 -61.1%

ROE

-438.3%TTM

2025 -492.1%2024 -169.4%2023 -108.2%

Recent news

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse 2026-09-15 · Newsfile Telo Genomics Grants Stock Options 2026-08-04 · Newsfile Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment 2026-07-16 · Newsfile Telo Genomics Announces Termination of Investor Relations Agreement 2026-06-26 · Newsfile Corp Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma 2026-04-14 · Newsfile Corp Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman 2026-03-31 · Newsfile Corp

Track TELO.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer